Article Versions Notes

Frerichs KA, Verkleij CPM, Dimopoulos MA, Marin Soto JA, Zweegman S, Young MH, Newhall KJ, Mutis T, van de Donk NWCJ. Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. Cancers. 2021; 13(10):2452. https://doi.org/10.3390/cancers13102452

Frerichs, Kristine A., Christie P. M. Verkleij, Meletios A. Dimopoulos, Jhon A. Marin Soto, Sonja Zweegman, Mary H. Young, Kathryn J. Newhall, Tuna Mutis, and Niels W. C. J. van de Donk. 2021. "Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients" Cancers 13, no. 10: 2452. https://doi.org/10.3390/cancers13102452

Frerichs, K. A., Verkleij, C. P. M., Dimopoulos, M. A., Marin Soto, J. A., Zweegman, S., Young, M. H., Newhall, K. J., Mutis, T., & van de Donk, N. W. C. J. (2021). Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. Cancers, 13(10), 2452. https://doi.org/10.3390/cancers13102452